Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.50 |
| ▸ | MMP13 | P45452 | 11/20 | 0.48 |
| ▸ | MMP1 | P03956 | 9/20 | 0.48 |
| ▸ | MMP9 | P14780 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757575 | 0.92 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9PKM | |
| SCHEMBL7509731 | 0.88 | MMP13 (0.47) | ADAM17MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL7552262 | 0.86 | ALDH1A1 (0.46) | ADAM17MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL7559733 | 0.86 | ALDH1A1 (0.46) | ADAM17MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL7578043 | 0.84 | HRH3 (0.54) | ADAM17MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL7505846 | 0.82 | ALDH1A1 (0.49) | MMP13MMP1ALDH1A1PKMKMT2A | |
| SCHEMBL7515028 | 0.82 | ALDH1A1 (0.53) | ADAM17MMP13MMP1ALDH1A1MMP2 | |
| SCHEMBL7549978 | 0.82 | ALDH1A1 (0.56) | ADAM17MMP13MMP1MMP9ALDH1A1 | |
| SCHEMBL7515093 | 0.82 | KCNH2 (0.46) | ALDH1A1PKMKMT2A | |
| Hydroxyamine SCHEMBL6861859 | 0.81 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6753337-B2 | INHIBITORS OF TNF-ALPHA CONVERTING ENZYME; TREATMENT OF ARTHRITIS, INFLAMMATION, INFLAMMATORY BOWEL DISEASE ETC, | WYETH HOLDINGS CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | AMERICAN CYANAMID COMPANY | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP13 16/4885MMP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.